{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:30:42Z","timestamp":1791181842575,"version":"4.1.0"},"reference-count":79,"publisher":"Oxford University Press (OUP)","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1093\/eurheartj\/ehp477","type":"journal-article","created":{"date-parts":[[2009,10,31]],"date-time":"2009-10-31T20:12:36Z","timestamp":1257019956000},"page":"2838-2844","source":"Crossref","is-referenced-by-count":136,"title":["Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies"],"prefix":"10.1093","volume":"30","author":[{"given":"Roland","family":"Klingenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6ran K.","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,10,30]]},"reference":[{"key":"key\n\t\t\t\t20170515121233_EHP477C1","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(06)68770-9","article-title":"Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data","volume":"367","author":"Lopez","year":"2006","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170515121233_EHP477C2","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170515121233_EHP477C3","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jama.290.7.891","article-title":"Major risk factors as antecedents of fatal and nonfatal coronary heart disease events","volume":"290","author":"Greenland","year":"2003","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170515121233_EHP477C4","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/art.20878","article-title":"Cardiovascular death in rheumatoid arthritis: a population-based study","volume":"52","author":"Maradit-Kremers","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20170515121233_EHP477C5","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa035611","article-title":"Premature coronary-artery atherosclerosis in systemic lupus erythematosus","volume":"349","author":"Asanuma","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170515121233_EHP477C6","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170515121233_EHP477C7","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.107.703389","article-title":"Independent impact of gout on mortality and risk for coronary heart disease","volume":"116","author":"Choi","year":"2007","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170515121233_EHP477C8","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ng1544","article-title":"MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction","volume":"37","author":"Swanberg","year":"2005","journal-title":"Nat Genet"},{"key":"key\n\t\t\t\t20170515121233_EHP477C9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/ng1524","article-title":"Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility","volume":"37","author":"Wang","year":"2005","journal-title":"Nat Genet"},{"key":"key\n\t\t\t\t20170515121233_EHP477C10","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1161\/01.ATV.0000150039.60906.02","article-title":"Polymorphisms of the interleukin-1beta gene affect the risk of myocardial infarction and ischemic stroke at young age and the response of mononuclear cells to stimulation in vitro","volume":"25","author":"Iacoviello","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key\n\t\t\t\t20170515121233_EHP477C11","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/ng1047","article-title":"Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction","volume":"32","author":"Ozaki","year":"2002","journal-title":"Nat Genet"},{"key":"key\n\t\t\t\t20170515121233_EHP477C12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa025079","article-title":"Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis","volume":"350","author":"Dwyer","year":"2004","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170515121233_EHP477C13","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/ng1311","article-title":"The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke","volume":"36","author":"Helgadottir","year":"2004","journal-title":"Nat Genet"},{"key":"key\n\t\t\t\t20170515121233_EHP477C14","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/ng1692","article-title":"A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction","volume":"38","author":"Helgadottir","year":"2006","journal-title":"Nat Genet"},{"key":"key\n\t\t\t\t20170515121233_EHP477C15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev.immunol.23.021704.115839","article-title":"TNF\/TNFR family members in costimulation of T cell responses","volume":"23","author":"Watts","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"key\n\t\t\t\t20170515121233_EHP477C16","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1146\/annurev.immunol.021908.132612","article-title":"Immunological and inflammatory functions of the interleukin-1 family","volume":"27","author":"Dinarello","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"key\n\t\t\t\t20170515121233_EHP477C17","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1161\/01.CIR.101.18.2149","article-title":"Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction","volume":"101","author":"Ridker","year":"2000","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170515121233_EHP477C18","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa022600","article-title":"Soluble CD40 ligand in acute coronary syndromes","volume":"348","author":"Heeschen","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170515121233_EHP477C19","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1182\/blood-2005-09-010629","article-title":"Platelet-derived LIGHT induces inflammatory responses in endothelial cells and monocytes","volume":"108","author":"Otterdal","year":"2006","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170515121233_EHP477C20","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1161\/01.ATV.0000204334.48195.6a","article-title":"Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization","volume":"26","author":"Sandberg","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key\n\t\t\t\t20170515121233_EHP477C21","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jacc.2007.09.058","article-title":"Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes","volume":"51","author":"Omland","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170515121233_EHP477C22","doi-asserted-by":"crossref","first-page":"e4442","DOI":"10.1371\/journal.pone.0004442","article-title":"Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction","volume":"4","author":"Secchiero","year":"2009","journal-title":"PLoS ONE"},{"key":"key\n\t\t\t\t20170515121233_EHP477C23","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1161\/01.CIR.0000125700.33637.B1","article-title":"Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors","volume":"109","author":"Waehre","year":"2004","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170515121233_EHP477C24","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/heart.88.5.467","article-title":"Increased plasma concentrations of interleukin-18 in acute coronary syndromes","volume":"88","author":"Mallat","year":"2002","journal-title":"Heart"},{"key":"key\n\t\t\t\t20170515121233_EHP477C25","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1161\/01.CIR.0000127958.21003.5A","article-title":"Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction","volume":"109","author":"Shimpo","year":"2004","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170515121233_EHP477C26","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1161\/CIRCULATIONAHA.105.590927","article-title":"Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study","volume":"114","author":"Blankenberg","year":"2006","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170515121233_EHP477C27","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1161\/ATVBAHA.109.184101","article-title":"Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993\u20132003","volume":"29","author":"Semb","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key\n\t\t\t\t20170515121233_EHP477C28","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1152\/physrev.00024.2005","article-title":"Cytokines in atherosclerosis: pathogenic and regulatory pathways","volume":"86","author":"Tedgui","year":"2006","journal-title":"Physiol Rev"},{"key":"key\n\t\t\t\t20170515121233_EHP477C29","first-page":"I204","article-title":"Deleterious effects of methylprednisolone in patients with myocardial infarction","volume":"53","author":"Roberts","year":"1976","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170515121233_EHP477C30","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1056\/NEJMra071667","article-title":"Myocardial reperfusion injury","volume":"357","author":"Yellon","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170515121233_EHP477C31","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1538-7836.2009.03404.x","article-title":"Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT)","volume":"7","author":"Ridker","year":"2009","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20170515121233_EHP477C32","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa052643","article-title":"Oral fingolimod (FTY720) for relapsing multiple sclerosis","volume":"355","author":"Kappos","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170515121233_EHP477C33","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1161\/CIRCULATIONAHA.106.641407","article-title":"FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice","volume":"115","author":"Nofer","year":"2007","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170515121233_EHP477C34","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1161\/01.ATV.0000254679.42583.88","article-title":"The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice","volume":"27","author":"Keul","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key\n\t\t\t\t20170515121233_EHP477C35","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1161\/ATVBAHA.107.149476","article-title":"Sphingosine-1-phosphate analogue FTY720 causes lymphocyte redistribution and hypercholesterolemia in ApoE-deficient mice","volume":"27","author":"Klingenberg","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key\n\t\t\t\t20170515121233_EHP477C36","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/ncpneph0217","article-title":"Drug insight: immunomodulatory effects of statins\u2014potential benefits for renal patients?","volume":"2","author":"Steffens","year":"2006","journal-title":"Nat Clin Pract Nephrol"},{"key":"key\n\t\t\t\t20170515121233_EHP477C37","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170515121233_EHP477C38","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1161\/CIRCULATIONAHA.106.628909","article-title":"Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial","volume":"114","author":"Morrow","year":"2006","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170515121233_EHP477C39","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa042000","article-title":"Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease","volume":"352","author":"Nissen","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170515121233_EHP477C40","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170515121233_EHP477C41","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","article-title":"Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial","volume":"373","author":"Ridker","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170515121233_EHP477C42","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.jacc.2007.02.025","article-title":"Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial","volume":"49","author":"Patti","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170515121233_EHP477C43","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol Ther"},{"key":"key\n\t\t\t\t20170515121233_EHP477C44","first-page":"1213","article-title":"Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis","volume":"32","author":"Jacobsson","year":"2005","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t20170515121233_EHP477C45","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/art.23281","article-title":"Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?","volume":"58","author":"Listing","year":"2008","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20170515121233_EHP477C46","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170515121233_EHP477C47","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1196\/annals.1351.039","article-title":"Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis","volume":"1069","author":"Seriolo","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"key\n\t\t\t\t20170515121233_EHP477C48","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.24492","article-title":"Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis","volume":"60","author":"van Eijk","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20170515121233_EHP477C49","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/rheumatology\/41.5.484","article-title":"Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis","volume":"41","author":"Catrina","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"key\n\t\t\t\t20170515121233_EHP477C50","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/01.CIR.103.2.276","article-title":"An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro","volume":"103","author":"Aikawa","year":"2001","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170515121233_EHP477C51","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/art.10388","article-title":"High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment","volume":"46","author":"Ziolkowska","year":"2002","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20170515121233_EHP477C52","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1161\/ATVBAHA.109.188185","article-title":"Osteoprotegerin promotes fibrous cap formation in atherosclerotic lesions of ApoE-deficient mice","volume":"29","author":"Ovchinnikova","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key\n\t\t\t\t20170515121233_EHP477C53","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170515121233_EHP477C54","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1136\/jnnp.2004.054882","article-title":"A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients","volume":"76","author":"Emsley","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key\n\t\t\t\t20170515121233_EHP477C55","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1161\/01.STR.0000236637.72124.3f","article-title":"Genetic and acquired inflammatory conditions are synergistically associated with early carotid atherosclerosis","volume":"37","author":"Markus","year":"2006","journal-title":"Stroke"},{"key":"key\n\t\t\t\t20170515121233_EHP477C56","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1161\/CIRCULATIONAHA.107.740233","article-title":"Anakinra a recombinant human interleukin-1 receptor antagonist inhibits apoptosis in experimental acute myocardial infarction","volume":"117","author":"Abbate","year":"2008","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170515121233_EHP477C57","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1745-6215-9-8","article-title":"Investigation of the effect of interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study)","volume":"9","author":"Crossman","year":"2008","journal-title":"Trials"},{"key":"key\n\t\t\t\t20170515121233_EHP477C58","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.prostaglandins.2007.01.003","article-title":"5-lipoxygenase: regulation and possible involvement in atherosclerosis","volume":"83","author":"Radmark","year":"2007","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"key\n\t\t\t\t20170515121233_EHP477C59","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/01.CIR.85.1.230","article-title":"Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation","volume":"85","author":"Carry","year":"1992","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170515121233_EHP477C60","doi-asserted-by":"crossref","first-page":"8161","DOI":"10.1073\/pnas.0602414103","article-title":"Expression of 5-lipoxygenase leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability","volume":"103","author":"Qiu","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t20170515121233_EHP477C61","doi-asserted-by":"crossref","first-page":"17501","DOI":"10.1073\/pnas.0505845102","article-title":"Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia","volume":"102","author":"Back","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t20170515121233_EHP477C62","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1001\/jama.293.18.2245","article-title":"Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial","volume":"293","author":"Hakonarson","year":"2005","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170515121233_EHP477C63","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170515121233_EHP477C64","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/nri2415","article-title":"The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models","volume":"8","author":"Weber","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"key\n\t\t\t\t20170515121233_EHP477C65","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00281-009-0143-x","article-title":"Cytokine network and T cell immunity in atherosclerosis","volume":"31","author":"Ait-Oufella","year":"2009","journal-title":"Semin Immunopathol"},{"key":"key\n\t\t\t\t20170515121233_EHP477C66","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1084\/jem.20052205","article-title":"Lymphocyte recruitment into the aortic wall before and during development of atherosclerosis is partially L-selectin dependent","volume":"203","author":"Galkina","year":"2006","journal-title":"J Exp Med"},{"key":"key\n\t\t\t\t20170515121233_EHP477C67","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.20080752","article-title":"Lymphotoxin beta receptor signaling promotes tertiary lymphoid organogenesis in the aorta adventitia of aged ApoE\u2212\/\u2212 mice","volume":"206","author":"Grabner","year":"2009","journal-title":"J Exp Med"},{"key":"key\n\t\t\t\t20170515121233_EHP477C68","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1093\/eurheartj\/ehl222","article-title":"Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes","volume":"27","author":"Mor","year":"2006","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170515121233_EHP477C69","doi-asserted-by":"crossref","first-page":"e779","DOI":"10.1371\/journal.pone.0000779","article-title":"Low numbers of FOXP3 positive regulatory T cells are present in all developmental stages of human atherosclerotic lesions","volume":"2","author":"de Boer","year":"2007","journal-title":"PLoS ONE"},{"key":"key\n\t\t\t\t20170515121233_EHP477C70","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.2337\/diabetes.54.6.1763","article-title":"A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes","volume":"54","author":"Herold","year":"2005","journal-title":"Diabetes"},{"key":"key\n\t\t\t\t20170515121233_EHP477C71","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1161\/CIRCULATIONAHA.106.627430","article-title":"Short-term treatment with anti-CD3 antibody reduces the development and progression of atherosclerosis in mice","volume":"114","author":"Steffens","year":"2006","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170515121233_EHP477C72","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.106.633263","article-title":"Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule","volume":"114","author":"Gotsman","year":"2006","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170515121233_EHP477C73","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1172\/JCI31344","article-title":"Proatherogenic immune responses are regulated by the PD-1\/PD-L pathway in mice","volume":"117","author":"Gotsman","year":"2007","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t20170515121233_EHP477C74","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1161\/01.ATV.0000251007.07648.81","article-title":"Interruption of the Tnfrsf4\/Tnfsf4 (OX40\/OX40L) pathway attenuates atherogenesis in low-density lipoprotein receptor-deficient mice","volume":"27","author":"van Wanrooij","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key\n\t\t\t\t20170515121233_EHP477C75","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1161\/CIRCULATIONAHA.107.699173","article-title":"CD137 is expressed in human atherosclerosis and promotes development of plaque inflammation in hypercholesterolemic mice","volume":"117","author":"Olofsson","year":"2008","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170515121233_EHP477C76","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1191\/0961203304lu1032oa","article-title":"Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients","volume":"13","author":"Sidiropoulos","year":"2004","journal-title":"Lupus"},{"key":"key\n\t\t\t\t20170515121233_EHP477C77","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1084\/jem.20060468","article-title":"Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells","volume":"203","author":"Seddiki","year":"2006","journal-title":"J Exp Med"},{"key":"key\n\t\t\t\t20170515121233_EHP477C78","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/978-1-59745-395-0_6","article-title":"Isolation, expansion, and characterization of human natural and adaptive regulatory T cells","volume":"380","author":"Gregori","year":"2007","journal-title":"Methods Mol Biol"},{"key":"key\n\t\t\t\t20170515121233_EHP477C79","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00281-009-0151-x","article-title":"Vaccination against atherosclerosis? Induction of atheroprotective immunity","volume":"31","author":"Hansson","year":"2009","journal-title":"Semin Immunopathol"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/30\/23\/2838\/17048650\/ehp477.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T10:47:33Z","timestamp":1558608453000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-lookup\/doi\/10.1093\/eurheartj\/ehp477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,30]]},"references-count":79,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2009,10,30]]},"published-print":{"date-parts":[[2009,12]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehp477","relation":{},"ISSN":["1522-9645","0195-668X"],"issn-type":[{"value":"1522-9645","type":"electronic"},{"value":"0195-668X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10,30]]}}}